Immunoconjugates comprising tyrosine kinase inhibitors

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

5303917, 5303919, 53038875, C07K 1628

Patent

active

055874592

ABSTRACT:
Immunoconjugates effective for treating cancers and autoimmune diseases in humans are provided which comprise a tyrosine kinase inhibitor linked to a ligand targeting a cell surface receptor which are specifically capable of inhibiting receptor associated tyrosine kinases.

REFERENCES:
patent: 4831117 (1989-05-01), Uckun
patent: 4841077 (1989-06-01), Ito et al.
patent: 4960908 (1990-10-01), Ito et al.
patent: 5331014 (1994-07-01), Kimura et al.
Akiyama et al., "Genistein, A Specific Inhibitor of Tyrosine-Specific Protein Kinases", J. Biol. Chem., 262, 5592 (1987).
Bolen et al., "Signal Transduction by the Src Family of Tyrosine Protein Kinases in Hematopoietic Cells", Cell Growth and Differentiation, 2, 409 (Aug. 1991).
Bolen et al., "The Src Family of Tyrosine Protein Kinases in Hematopoietic Signal Transduction", Faseb J., 6, 3403 (1992).
Bolen et al., "Expression and Interactions of the Src Family of Tyrosine Protein Kinases inT Lymphocytes", Adv. Can. Res., 57, 103 (1991).
Campbell et al., "Protein Tyrosine Phosphorylation is Induced in Murine B Lymphocytes in Response to Stimulation with Anti-Immunoglobulin", Embo. J., 9, 2125 (1990).
Chae et al., "Role of Tyrosine Phosphorylation in Radiation-induced Activation of c-jun Protooncogene in Human Lymphohematopoietic Precursor Cells", Cancer Research, 53, 447 (Feb. 1, 1993).
Constantinou et al., "Induction of Differentiation and DNA Breakage in Human HL-60 and K-562 Leukemia Cells by Genistein (Meeting Abstract)", Proc. Ann. Meet. Am. Assoc. Cancer Res., 31, A2605 (1990).
Constantinou et al., "Induction of Differentiation and DNA Strand Breakage in Human HL-60 and K-562 Leukemia Cells by Genistein", Cancer Res., 50, 2618 (1990).
Honma et al., "Herbimycin A, an Inhibitor of Tyrosine Kinase, Prolongs Survival of Mice Inoculated with Myeloid Leukemia C1 Cells with High Expression of v-abl, Tyrosine Kinase", Cancer Res., 52, 4017 (1992).
Hunter et al., "Protein Tyrosine Kinases", Annu. Rev. Biochem., 54, 897 (1985).
Okabe et al., "Effects of Herbimycin A, an Antagonist of Tyrosine Kinase, on bcr/abl Oncoprotein-Associated Cell Proliferations: Abrogative Effect on the Transformation of Murine Hematopoietic Cells by Transfection of a Retroviral Vector Expressing Oncoprotein P210.sup.bcr/abl and Preferential Inhibition on Ph.sup.1 -Positive Leukemia Cell Growth", Blood, 80, 1330 (1992).
Okabe et al., "New Insight into Oncoprotein-Targeted Antitumor Effect: Herbimycin A as an Antagonist of Protein Tyrosine Kinase against Ph.sup.1 -Positive Leukemia Cells", Leukemia and Lymphoma, 12, 41 (1993).
Otani et al., "Tyrosine Kinase (s) regulate Apoptosis and bcl-2 Expression in a Growth Factor-Dependent Cell Line", J. Biol. Chem., 268, 22733 (Oct. 21, 1993).
Peterson et al., "Genistein Inhibition of the Growth of Human Breast Cancer Cells: Independence from Estrogen Receptors and the Multi-Drug Resistance Gene", Biochem. Biophys. Res. Com., 179, 661 (1991).
Schiven et al., "Reactive Oxygen Intermediates Activate NF-.kappa.B in a Tyrosine Kinase-Dependent Mechanism and in Combination with Vanadate Activate the p56.sup.lck and p59.sup.fyn Tyrosine Kinases in Human Lymphocytes", Blood, 82, 1212 (Aug. 15, 1993).
Spinozzi et al., "The Natural Tyrosine Kinase Inhibitor Genistein Produces Cell Cycle Arrest and Apoptosis in Jurkat T-Leukemia Cells", Leuk. Res., 18, 431 (1994).
Takekura et al., "Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells", Int. J. Cancer , 47, 938 (1991).
Thomas, "New Horizons in Cancer Therapy", Drugs of Today, 28, 311 (1992).
Traganos et al., "Effects of Genistein on the Growth and Cell Cycle Progression of Normal Human Lymphocytes and Human Leukemic MOLT-4 and HL-60 Cells", Cancer Res., 52, 6200 (1992).
Uckun et al., "Radiation Damage Repair Capacity of Primary Clonogenic Blasts in Acute Lymphoblastic Leukemia", Cancer Research, 53, 1431 (Mar. 15, 1993).
Uckun et al., "Signal Transduction Through the CD19 Receptor during Discrete Developmental Stages of Human B-cell Ontogeny", The Journal of Biological Chemistry, 268, 21172 (Oct. 5, 1993).
Uckun et al., "Ionizing-Radiation Stimulates Unidentified Tyrosine-Specific Protein Kinases in Human Lymphocyte-B Precursors, Triggering Apoptosis and Clonogenic Cell-Death", PNAS USA, 89, 9005 (Oct. 1992).
Uckun et al., "Tyrosine Phosphorylation is a Mandatory Proximal Step in Radiation-Induced Activation of the Protein Kinase C Signaling Pathway in Human B-Lymphocyte Precursors", PNAS USA, 90, 252 (Jan. 1993).
Waddick et al., "Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis", Radiation Research, 136, 313 (Dec. 27, 1993).
Yamanashi et al., "Association of B Cell Antigen Receptor with Protein Tyrosine Kinase Lyn", Science, 251, 192 (1991).
Canevari et al., Annals of Oncology, vol. 5, pp. 698-701, (1994).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immunoconjugates comprising tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoconjugates comprising tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoconjugates comprising tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1179352

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.